Ticker LaunchIPO · BOLT
Bolt Biotherapeutics, Inc.
Formerly Bolt Therapeutics, Inc.
Bolt Biotherapeutics, Inc. (BOLT) priced its initial public offering on Feb 5, 2021 at $20.00 per share, above its $18.00–$19.00 range, raising $230M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $690.4M. Cooley advised the company and Davis Polk advised the underwriters.
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted Boltbody Immune-Stimulating Antibody Conjugates that activate myeloid cells to kill tumor cells and engage the adaptive immune system. Its lead candidate, BDC-1001, is a HER2-targeting conjugate built on a trastuzumab biosimilar.
- Status
- IPO
- Ticker
- BOLT
- Exchange
- Nasdaq Global Select
- Priced
- Feb 5, 2021
- IPO price
- $20.00
- Price range
- $18.00–$19.00
- Raised
- $230M
- Market cap at IPO price
- $690.4M
- First filed
- Jan 15, 2021
- Company counsel
- Cooley
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 15, 2021
- Latest amendment Feb 3, 2021
- Final prospectus (424B4) Feb 5, 2021
- All filings on EDGAR CIK 1641281
Other Biotech & pharma IPOs in 2021
- Immunocore Holdings plcIMCR · Feb 8, 2021
- Elicio Therapeutics, Inc.ANGN · Feb 5, 2021 · $80M
- Evaxion A/SEVAX · Feb 5, 2021
- Sana Biotechnology, Inc.SANA · Feb 5, 2021 · $587.5M
- Landos Biopharma, Inc.LABP · Feb 4, 2021 · $100M
- Faeth Therapeutics, Inc.SNSE · Feb 4, 2021 · $133M